While pharmacological inhibition, silencing or knockdown of ATG5 in hepatocytes results in increased triglyceride levels and lipid droplet accumulation [53], WAT expression of ATG5 is increased in obesity, especially in the VAT depot [54], and is a key regulator of adipogenesis. The gene discussed is ATG5; the disease is obesity disorder.